Showing 4721-4730 of 8223 results for "".
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.
- Late-Breaking Data: Lilly and Dermira’s Lebrikizumab Improves Itch, Sleep and Quality of Life in ADhttps://practicaldermatology.com/news/late-breaking-data-lilly-and-dermiras-lebrikizumab-improves-itch-sleep-and-quality-of-life-in-ad-1/2460424/Lilly and Dermira’s Lebrikizumab improves itch, sleep and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to a Phase 2b clinical trial presented during a virtual late-breaking, oral session at the American Academy of Dermatology (AAD) 2020 Annual Meetin
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th
- Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumabhttps://practicaldermatology.com/news/bimekizumab-phase-3-data-show-superior-skin-clearance-in-moderate-to-severe-psoriasis/2460421/UCB shared first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior
- Dermata Reports Positive Results for Once-Weekly Topical Application of DMT310 in Acnehttps://practicaldermatology.com/news/dermata-reports-positive-results-for-once-weekly-topical-application-of-dmt310-in-acne/2460417/Dermata Therapeutics' lead clinical candidate, DMT310, performed well in a Phase 2b study of moderate-to-severe acne vulgaris. Once-weekly DMT310 achieved Investigator Global Assessment (IGA) success (2-point change & 0 or 1) in 44.4 percent of patients versus 17.8 percent
- Dermavant Completes Enrollment for Long-Term Safety Study of Tapinarof in Adult Psoriasishttps://practicaldermatology.com/news/dermavant-completes-enrollment-for-long-term-safety-study-of-tapinarof-in-adult-psoriasis/2460416/Patient enrollment in Dermavant’s long-term safety study of tapinarof is now complete, the company says. Tapinarof is a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) being investigated for use in adult patients diagnosed with plaq
- Promising Data from Dermavant's Phase 2b Study of Tapinarof in Psoriasishttps://practicaldermatology.com/news/promising-data-from-dermavants-phase-2b-study-of-tapinorof-in-psoriasis/2460405/Patients treated with once daily tapinarof 1% demonstrated improvement in PASI75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase
- FDA Approves Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe ADhttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-ad/2460404/The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Dupixent comes in two doses, prescribed based on weight (300 mg every four weeks for children ≥15 to <30 kg and 200 mg eve
- Congrats: Dr. Paul Bergstresser Receives ASA’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-paul-bergstresser-receives-asas-david-martin-carter-mentor-award/2460401/Dr. Paul Bergstresser of UT Southwestern Medical Center in Dallas, Texas is the recipient of the American Skin Association’s (ASA) 2020 David Martin Carter Mentor Award Since 1989, ASA's David Martin Carter Mentor Award has honored members of the derma
- Industry Responds to COVID-19: Dial Donates Products to FEMA, Encourages Americans to Participate in #IWashMyHandsFor Social Campaignhttps://practicaldermatology.com/news/industry-responds-dial-donates-products-to-fema-encourages-americans-to-participate-in-iwashmyhandsfor-social-campaign/2460398/Dial will donate more than 600,000 units of liquid hand soap, bar soap and body wash products to FEMA, supporting their mission to help people during disasters. In March 2020 Henkel announced a comprehensive